LENZ Therapeutics, Inc. (LENZ) Profit Margins
Over the twelve months to 2026-06-30, LENZ Therapeutics, Inc. (LENZ) had operating margin -631.7%, net margin -586.7%, free cash flow margin -532.8%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
LENZLENZ Therapeutics, Inc.Follow LENZ — free
—
Price chart with a free account
- Market cap
- 99.3M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
| Line | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|
| Gross margin | 97.8% | — | |
| Operating margin | -477.5% | -631.7% | |
| Net margin | -430.3% | -586.7% | |
| FCF margin | -366.7% | -532.8% |
USD millions · SEC XBRL
LENZ Therapeutics, Inc. — questions
- What is LENZ Therapeutics, Inc.'s operating margin?
- -631.7% over the twelve months to 2026-06-30.
- What is LENZ Therapeutics, Inc.'s net profit margin?
- -586.7% over the twelve months to 2026-06-30.
Every figure on this page comes from LENZ Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.